vsg not another nal

Like NAL, they both are small cap in health sector with a postive ann abt patent grant today, but that's where the similarity ends.

NAL's survival is hanging by a Line of Credit, while VSG has great fundementals, good management, and has positive gross profits in FY06, FY07. It has a NTA of 7c. Has plenty of cash in hand.

The company is very aggresive in its product marketing.
http://www.visiomed.com.au/investors/asxReleases.php

Pleanty of upside with its following 4 products/services:
Funhaler, Microderm, Medical Imaging & croEYE.

The ann was in late in market, most investors have not have time to look at it. It should do well tomorrow.